Skip to main content

Remote Job Finders (RJF)

Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly
Scroll to top